Pesquisar
Grifols SA
GRFSAdicionar à lista de desejos
7.310USD
-0.090-1.22%
Fechamento 09-18 16:00（ET）
1.88BValor de mercado
9.40P/L TTM
Mais detalhes de Grifols SA Empresa
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Grifols SA Perfil
Código da empresaGRFS
Nome da EmpresaGrifols SA
Data de listagemMay 17, 2006
CEOAbia (Jose Ignacio)
Número de funcionários23833
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 17
EndereçoParque Empresarial Can Sant Joan
CidadeSANT CUGAT DEL VALLES
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSpain
Código postal08174
Telefone34935710000
Sitehttps://www.grifols.com/
Código da empresaGRFS
Data de listagemMay 17, 2006
CEOAbia (Jose Ignacio)
Executivos da empresa Grifols SA
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Mr. Tomas Daga Gelabert
Mr. Tomas Daga Gelabert
Other External Director
Other External Director
--
--
Mr. Raimon Grifols Roura
Mr. Raimon Grifols Roura
Vice Chairman of the Board, Proprietary Director
Vice Chairman of the Board, Proprietary Director
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Assistant Secretary of the Board of Directors
Non-Member Assistant Secretary of the Board of Directors
--
--
Mr. Ignacio Ramal Subira
Mr. Ignacio Ramal Subira
Chief Internal Audit & Enterprise Risk Management
Chief Internal Audit & Enterprise Risk Management
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Enrique De La Torre
Mr. Enrique De La Torre
Chief Compliance Officer
Chief Compliance Officer
--
--
Mr. Roland Wandeler, Ph.D.
Mr. Roland Wandeler, Ph.D.
President - Biopharma
President - Biopharma
--
--
Ms. Irene Roche Font
Ms. Irene Roche Font
Vice President - Accounting and Financial Services
Vice President - Accounting and Financial Services
--
--
Ms. Montseratt Ribas Loveras
Ms. Montseratt Ribas Loveras
Chief Communication and Reputation Officer
Chief Communication and Reputation Officer
--
--
Dr. Ester Masllorens Llinas
Dr. Ester Masllorens Llinas
Independent Director
Independent Director
--
--
Ms. Joanna Susan Le Couilliard
Ms. Joanna Susan Le Couilliard
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Grifols SA?
Os cinco principais acionistas de Grifols SA são: Mr. Enrique De La Torre
Quantas instituições possuem ações da Grifols SA (GRFS)?
Em 2026Q1, 346 instituições possuíam ações da Grifols SA, com valor de mercado aproximado de 148.94M, representando 57.68% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -8688154.00.